Subgroup analyses of VGPR rates comparing ibrutinib plus rituximab vs ibrutinib monotherapy (above), and the impact of CXCR4 mutations on VGPR within each treatment arm (below). False discovery rate correction was applied for multiple comparisons: 7 subgroup comparisons (above) and 2 (below).